



The Nifty ended 1.73% down at 17173.65. It opened gap-down and continued declining towards finishing off with a Doji candle. Opening with gap down below the critical support placed around 17350 suggesting weakness likely to persist. Hence staying cautious on rise is advised. The Nifty immediate trading range likely to be 17000-17350.

On the Nifty hourly chart, oversold leading indicator pointing towards pullback, however, direction of the ADX suggesting pullback may again find sellers around 17350 levels. Higher resistance is placed around 17450 levels.

Nifty patterns on multiple periods suggesting; candle on daily pointing towards range bound oscillation with a negative bias. Downside supports are placed around 17100 and 17000 levels.

Nifty Crucial Supports & Resistances-

Supports- 17100, 17000 Resistances- 17350, 17450

Open Positional Calls-

T+14 INST POSITIONAL BUY-

| Cash Segment | TATA CONSUMER @ 800-790, TGT- 855, Closing SL- below 765

T+14 INST POSITIONAL BUY-

| Cash Segment | SAIL @ 111-110, TGT- 120, Closing SL- below 100

Key Contents	Page No.
Result Update	4
Domestic News	5

Nifty Intraday Chart



Market in Retrospect

India's stock benchmarks declined for fourth consecutive session and logged worst day in six weeks. Information technology and banking stocks declined, as Infosys and HDFC Bank fell after Q4 numbers.

Nifty index ended 1.73% lower at 17,174. The broader markets represented by the Nifty 500 Index ended 1.40% lower, ending at 14,926. Among the sectorial indices, Nifty PSE was the top gainer, gaining by 1.14%, followed by Nifty Energy which was gaining by 0.81%. Nifty IT was the top loser, losing by 4.58%.

NTPC was the top gainer, gaining by 6.01%, followed by SBI Life and HDFC Life which was gaining by 2.31% & 1.67% respectively. Infosys was the top loser, losing by 7.27%, followed by HDFC and HDFC Bank which fell by 4.84% & 4.74% respectively.

The Advance : Decline ratio stood at 871:1353

Market Turnover (In Crore) 18-04-2022

Name	Last	Previous
NSE Cash	71333.94	56580.43
NSE F&O	6316023.93	18594250.53
BSE Cash	5,202.49	4,199.36
BSE F&O	146.42	40.83

FII Derivatives Flow (In Crore) 18-04-2022

Instrument	Purchase	Sale	Net
Index Future	3666.24	4068.89	402.65
Index Option	460931.42	458611.46	2319.96
Stock Future	13793.49	14705.60	912.11
Stock Option	11583.36	11065.99	517.37

Institutional Flow (In Crore) 18-04-2022

Institution	Purchase	Sale	Net
FII	7589.12	13976.57	6387.45
DII	9637.18	6295.22	3341.96

NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
NTPC	6.01	6.32	82098517	20333640
SBI Life Insurance	2.31	5.82	2382085	1338272
HDFC Life Insurance	1.67	2.74	5765896	3251778
Coal India	1.53	0.68	13052104	17476490
Tata Steel	1.49	0.77	8070042	5336933

NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Apollo Hospitals	4.00	0.40	579482	627652
Tech Mahindra	4.67	8.44	3968044	3091984
HDFC Bank	4.74	8.00	22810188	15916500
HDFC	4.84	8.09	9158650	6296818
Infosys	7.27	10.47	30523965	6378255

Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.asp>

Sensex Intraday Chart



Market in Detailed (Updated after 4:00 PM)

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	57166.74	1172.19	2.01	3.16	1.20	4.88	19.22
Nifty	17173.65	302.00	1.73	2.64	0.66	4.26	19.60
BSE M Cap	24747.35	237.90	0.95	1.29	6.15	5.13	24.08
BSE S Cap	29223.81	297.79	1.01	0.85	7.34	5.58	40.46
Nifty MC 100	30473.55	322.75	1.05	1.42	7.80	4.74	29.58
BSE Auto	24458.70	95.02	0.39	0.70	6.48	6.98	10.49
BSE Capgoods	28102.96	180.05	0.64	1.79	3.81	8.98	37.05
BSE FMCG	14168.10	91.05	0.65	2.34	7.89	1.69	10.11
BSE Metal	22972.42	65.95	0.29	0.31	5.60	12.92	45.59
BSE Oil&Gas	19846.27	63.38	0.32	2.17	10.56	5.16	36.15
BSE Healthcare	24700.83	188.57	0.76	0.60	2.87	4.14	10.27
BSE Power	4876.11	94.17	1.97	9.41	25.04	26.75	103.24
BSE Realty	3640.40	44.42	1.21	3.22	8.42	9.92	45.48
BSE ConsDur	42645.73	126.03	0.29	0.20	1.60	6.96	33.59
BSE Bank	42348.95	725.70	1.68	1.64	4.55	3.25	17.35
BSE IT	32952.78	1646.04	4.76	7.70	8.02	14.28	23.22

Bond Markets

Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	2.86	0.03	1.10	2.82	32.99	52.58	80.94
UK	1.89	0.00	0.00	7.94	19.86	64.26	156.31
Brazil	5.36	0.01	0.26	0.62	1.23	9.74	28.00
Japan	0.25	0.00	1.66	1.66	17.23	71.33	163.44
Australia	2.97	0.00	0.00	1.30	15.21	52.54	71.18
India	7.16	0.06	0.83	0.83	5.58	7.97	17.53
Switzerland	0.86	0.00	0.00	19.25	122.66	3066.67	451.85
Germany	0.84	0.00	0.00	19.10	153.61	1930.44	390.35

Currency

Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	76.26	0.08	0.11	0.40	0.60	2.20	1.81
USD Index	100.57	0.07	0.07	0.78	2.38	5.06	9.85
YUAN	6.37	0.01	0.09	0.07	0.07	0.20	2.27
GBP	1.30	0.00	0.19	0.04	1.09	4.13	6.80
EUR	1.08	0.00	0.06	0.74	2.24	4.61	10.25
YEN	126.64	0.18	0.14	1.00	5.90	9.50	14.58

Freight

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	2137.00	69.00	3.34	3.69	20.53	21.15	8.01
Baltic Dirty	1714.00	14.00	0.81	3.69	34.01	145.56	181.91
SG Dubai HY	18.60	0.11	0.59	1.01	68.94	167.24	2315.58

Global Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	34451.23	113.36	0.33	0.38	2.70	4.07	1.22
Nasdaq	13351.08	292.51	2.14	3.93	3.11	10.36	4.90
S&P 500	4392.59	54.00	1.21	2.39	3.05	5.80	5.33
FTSE100	7616.38	35.58	0.47	0.86	6.14	0.97	9.06
CAC40	6589.35	47.21	0.72	1.98	3.69	7.75	5.70
DAX	14163.85	87.41	0.62	0.61	1.77	10.83	7.15
Mexico IPC	54172.62	265.37	0.49	2.28	2.58	0.80	12.09
Brazil Bovespa	116181.6	0.00	0.00	2.26	6.63	8.65	3.74
Russian RTS	943.09	12.02	1.26	7.24	NA	31.01	36.98
Japan Nikkei	26799.71	293.48	1.08	0.08	0.10	2.43	9.72
Hang Seng	21518.08	143.71	0.67	1.33	16.85	11.75	25.27
Taiwan Index	16898.87	105.31	0.62	0.88	3.19	7.29	2.11
Shanghai Comp	3195.52	15.72	0.49	0.90	1.71	10.19	8.11
KOSPI	2693.21	2.85	0.11	0.00	0.51	5.24	15.81
Malaysia KLCI	1581.14	7.87	0.50	1.46	0.64	3.32	1.20
Jakarta Comp	7275.29	39.76	0.55	0.89	4.61	10.37	20.20
Philippine SE	6996.11	11.21	0.16	1.01	0.16	3.66	8.30
Thai Exch	1668.06	6.28	0.38	1.95	0.62	0.59	5.91

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	106.82	0.20	0.19	8.64	1.96	24.96	69.10
BRENT Crude	111.92	0.14	0.13	8.81	6.44	31.45	80.45
Natural Gas	7.54	0.25	3.36	20.18	53.92	88.25	202.65

LME

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1993.60	15.79	0.80	2.07	3.77	9.94	12.24
Silver(\$/Ounce)	26.06	0.54	2.10	3.93	4.48	11.13	0.45
Aluminium	3271.50	61.00	1.90	2.67	0.37	9.92	41.81
Copper	10297.50	13.50	0.13	0.16	4.07	5.83	13.40
Zinc	4475.00	50.00	1.10	6.45	18.12	26.56	59.78
Lead	2440.25	13.50	0.55	2.71	8.69	3.26	23.64

Agro Commodities

Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	221.25	2.50	1.12	4.45	0.73	7.23	59.40
Cotton	142.95	2.24	1.59	9.07	16.19	24.67	76.03
Sugar	19.96	0.07	0.35	1.53	6.11	9.67	32.19
Wheat	1125.75	21.25	1.92	6.38	7.75	48.22	75.97
Soybean	1675.25	10.00	0.60	0.43	1.79	21.66	35.18

Mindtree

Mindtree on its consolidated net profit for the quarter ended March 2022 jumped 49.1 per cent to Rs 473.1 crore compared with Rs 317.3 crore in the same quarter last year. Sequentially, the profit figure was up 8.1 per cent. Revenue from operations for the quarter stood at Rs 2,897.4 crore, up 37.4 per cent from Rs 2,109.3 crore in the corresponding quarter a year ago. Quarter on quarter (QoQ), the growth came in at 5.4 per cent. The board of directors of Mindtree also recommended a final dividend of Rs 27 per equity share for the financial year ended March 31, 2022. The dividend is subject to the approval of shareholders.

Maruti Suzuki hikes vehicle prices by up to 1.9% amid rising input costs

Maruti Suzuki India (MSI) has increased prices of its entire model range, between 0.9 per cent to 1.9 per cent, with immediate effect. The company, which currently sells a range of vehicles from Alto to S-Cross, said it has taken the decision to hike prices due to an increase in input costs. The weighted average price rise, with effect from April 18, in ex-showroom prices (New Delhi) across models is 1.3 per cent. MSI has already hiked vehicle prices by around 8.8 per cent from January 2021 to March 2022, owing to constant increase in input costs. Over the past year, the cost of the company's vehicles continues to be adversely impacted due to increase in various input costs. Last week Mahindra & Mahindra hiked vehicle prices by 2.5 per cent, entailing an increase of up to Rs 63,000. Similarly, Toyota Kirloskar Motor has increased prices of its entire model range by up to 4 per cent from April 1.

L&T Infotech and Mindtree to merge to create \$22-bn firm

Larsen & Toubro Ltd. is weighing a merger between two of its publicly traded software firms, according to people familiar with the matter, as the Indian conglomerate seeks scale to compete with global digital giants. The boards of Mindtree Ltd. and Larsen & Toubro Infotech Ltd., two software units controlled by the Mumbai-based engineering firm, could consider share swap ratios for the merger as early as next week, one of the people said, asking not to be identified as the information is not public. Larsen acquired control of Mindtree in 2019. The conglomerate holds about a 61% stake in the company, which has a market value of \$8.3 billion, and has around 74% of L&T Infotech, which has a market capitalization of \$13.6 billion. The two companies have minimal overlap in businesses or clients, and a tie-up would give them better pricing power and lower costs.

Zydus Lifesciences gets USFDA nod for generic product

Zydus Lifesciences Ltd on Monday said it has received final approval from the US health regulator to market its generic version of Cyanocobalamin injection which is used to treat and prevent vitamin B12 deficiency caused by pernicious anemia. The approval granted by the US Food and Drug Administration (USFDA) is for Cyanocobalamin injection in strengths of 1,000 mcg/ml, 10,000 mcg/10 ml and 30,000 mcg/30 ml multiple-dose vials. The company said Cyanocobalamin injection is used to treat and prevent lack of vitamin B12 that may be caused due to pernicious anemia lack of a natural substance needed to absorb vitamin B12 from the intestine, certain diseases, infections or medications that decrease the amount of vitamin B12 absorbed from food. Zydus Lifesciences group now has 331 approvals and has so far filed over 400 abbreviated new drug applications since the commencement of the filing process in FY 2003-04.

Lupin gets USFDA nod to market drug used to treat chronic hepatitis B

Lupin has received approval from the US health regulator to market Tenofovir Alafenamide tablets, used to treat chronic hepatitis B virus infection, in the American market. The company has received tentative approval from the United States Food and Drug Administration (FDA) for its abbreviated new drug application for Tenofovir Alafenamide tablets (25 mg). The Mumbai-based company's product is the generic equivalent of Gilead Sciences' Vemlidy tablets. The product will be manufactured at company's Nagpur-based facility. As per IQVIA MAT December 2021, Tenofovir Alafenamide tablets had estimated annual sales of USD 484.2 million in the US.

Sanofi India names Rodolfo Hrosz managing director effective June 1

Sanofi India (SIL) announced its Board of Directors has appointed Rodolfo Hrosz as the Company's new Managing Director with effect from June 1, 2022, subject to regulatory approvals. He will transition from being Sanofi's General Manager, Consumer Healthcare business in Brazil to his new role in India as soon as the applicable regulatory approvals are in place.

JSPL's steel production rises in March quarter

Jindal Steel and Power Limited (JSPL) on Monday posted a 2 per cent rise in steel production at 2.11 million tonnes in the quarter ended March 2022. Its sales also registered a growth of 8 per cent at 2.07 Million Tonnes (MT) in the January-March period. In financial year 2021-22, the company produced a record 8.1 MT of steel while sales were at a record 7.63 MT. Despite several challenges throughout FY22, JSPL managed to meet its production guidance breaching the 8 MT mark for the first time. For the fifth consecutive year, JSPL has also posted spectacular growth in annual steel sales on a year-on-year basis.

Coal-based power generation rises in March

Coal-based power generation rose 3.12 per cent to 1,00,276 million units in March compared to the year-ago period, according to official data. Thermal power generation stood at 97,238 MU (Million Units) in the same period a year ago. In February this year, it stood at 85,534 MU. Coal accounts for over 70 per cent of the country's electricity output and utilities account for around 75 per cent of country's coal consumption. According to the monthly statistics (provisional) of the coal ministry, coal-based power generation registered a growth of 35 per cent in March this year compared to March 2020. The rise was 3.12 per cent compared to the power generation witnessed in March 2021. In March this year, the overall power generation was 29.02 per cent higher than the power generated in March 2020 and 6.35 per cent more than power generated in March 2021.

Analyst Certification:

We /I, Jaydeb Dey and Shreyansh N. Mehta Research Analyst(S) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document

to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report or at the time of Public Appearance.

SMIFS does not have proprietary trades but may at a future date, opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/short position in the above Scrip(s) and therefore should be considered as interested.

The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing, however the same shall have no bearing whatsoever on the specific recommendations made by the analysts, as the recommendations made by the analysts are completely independent views of the Associates of SMIFS even though there might exist an inherent conflict of interest in some of the stocks mentioned in the Research Report.

The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.mcxindia.com and/or www.icex.com.

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

Specific Disclosures

- SMIFS, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- SMIFS, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company.
- SMIFS, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months.
- SMIFS, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as director/officer/employee in the subject company
- SMIFS has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- SMIFS has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- SMIFS has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months.
- SMIFS has not received any compensation or other benefits from third party in connection with the research report.
- SMIFS has not engaged in market making activity for the subject company

Analyst holding in stock: **NO**

Key to SMIFS Investment Rankings

Buy: Return >15%, Accumulate: Return between 5% to 15%, Reduce: Return between -5% to +5%, Sell: Return < -5%

Contact us:

SMIFS Limited. (<https://www.smifs.com/>)

Compliance Officer:

Sudipto Datta,

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5401 /91 33 6634 5401

Email Id.: compliance@smifs.com
